Addressing Common Concerns About Medication

ADDYI can cause serious side effects, including: See “What is the most important information I should know about ADDYI?” This is not a complete list of side effects.

What women are saying

The drug’s approval has also raised a simpler question: What changed, exactly, between those two rejections and last night? The most obvious answer is good public relations. Even the Score, which launched in 2013, has framed the issue as one of “women’s sexual health equity.” The group notes on its site that the World Health Organization considers “[pursuit of] a satisfying, safe and pleasurable sexual life” to be a human right, and has successfully solicited letters of support to the FDA from the editor of The Journal of Sexual Medicine, the president of the National Organization for Women, and members of Congress.

What causes low libido in women?

What do females use instead of Viagra?

ADDYI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women < 65 years of age who have not had problems with low sexual desire in the past, no matter the type of sexual activity, situation, or sexual partner, and it is troubling to them.

Product	Dosage	Quantity + Bonus	Price
Viagra Oral Jelly	100mg	63 + 7 Sachets	190.54€ 181.47€	Buy
Viagra Generic	50mg	180 + 8 Pills	158.82€ 151.26€	Buy
Viagra Generic	100mg	360 + 10 Pills	330.21€ 314.49€	Buy
Viagra Super Active	100mg	120 + 16 Pills	198.37€ 188.92€	Buy
Viagra Professional	100mg	60 + 2 Pills	146.74€ 139.75€	Buy
Viagra Super Active	100mg	60 + 8 Pills	116.84€ 111.28€	Buy
Viagra Generic	150mg	10 Pills	36.73€ 34.98€	Buy
Viagra Generic	150mg	60 + 4 Pills	111.25€ 105.95€	Buy
Viagra Generic	200mg	120 + 8 Pills	204.80€ 195.05€	Buy
Viagra Generic	150mg	90 + 6 Pills	147.18€ 140.17€	Buy
Viagra Generic	50mg	30 + 4 Pills	54.26€ 51.68€	Buy
Viagra Oral Jelly	100mg	10 Sachets	46.36€ 44.15€	Buy
Viagra Generic	200mg	60 + 4 Pills	125.19€ 119.23€	Buy

Their low sexual desire is not due to a medical or mental health problem, problems in the relationship, medicine or other drug use. ADDYI is not for use in men or to improve sexual performance. Female sexual arousal disorder (FSAD) FSAD, as described in the Diagnostic and Statistical Manual 4th Edition (DSM-IV), is a condition characterized as a persistent or recurrent inability to attain or maintain sufficient genital arousal (an adequate lubrication-swelling response) during sexual activity, frequently resulting in distress or interpersonal difficulty. Of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction (ED) in men. There are currently no FDA-approved therapies for FSAD. A meta-analysis of 95 studies from 2000-2014 indicated prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 41%, and difficulty with arousal alone is 23%.1 Market research estimates: 33% of US women aged 21 to 60 (~ 20 million women), experience symptoms of low or no sexual arousal.2,310 million women in the US are considered distressed and actively seeking treatment.2 33% of US women aged 21 to 60 (~ 20 million women), experience symptoms of low or no sexual arousal.2,3 10 million women in the US are considered distressed and actively seeking treatment.2 To put the market opportunity for an FDA-approved FSAD treatment in context, a PDE5 inhibitor utilized in an ED medication for men – Viagra® — peaked at $2.05 billion in sales in 2012.4 Orally administered sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, received FDA approval in 1998 for the treatment of erectile dysfunction in men and is marketed under the brand name Viagra®. Given the underlying pathophysiologic similarities of ED and FSAD, using sildenafil to direct blood to the genitals before sexual activity could provide a potential improvement in genital arousal response and overall sexual experience for women as it does in men. Sildenafil Cream, 3.6% is an investigational proprietary topical formulation of sildenafil being developed as a first-in-category option for women for the treatment of FSAD. Unlike the oral formulations of PDE-5 inhibitors, sildenafil viagra price Sildenafil Cream is applied locally to the vaginal tissue and is designed to facilitate vasodilation and increased blood flow directly to the genital tissue to improve the physical arousal response symptoms commonly associated with FSAD while avoiding systemic side effects observed with oral formulations of sildenafil. Phase 1 and Phase 2a Clinical Studies, Previously Completed In a Phase 1 clinical study in 20 healthy post-menopausal women, topical sildenafil cream was safe and well tolerated at clinically relevant doses, and study subjects reported favorable product characteristics: easy to use and readily absorbed. In a Phase 2a study in women with FSAD (15 pre-menopausal and 16 post-menopausal), Sildenafil Cream increased measurable blood flow to the genital tissue compared to placebo cream. Further, data from a thermography study in healthy women demonstrated significantly greater increases in genital temperature after administration of Sildenafil Cream compared to placebo cream, indicating a positive impact on genital blood flow during the 30-minute testing session, with statistical separation from placebo within the first 15 minutes after dosing.

• Research is ongoing into new drug targets, like melanocortins and oxytocin.
• Lybrido and Lybridos were combination drugs (testosterone/sildenafil) investigated.
• The EROS-CTD device is an example of a non-hormonal, device-based treatment.
• Gene therapy and other novel approaches are in very early stages of research.
• Future treatments may offer more personalized approaches based on individual biology.
• Digital therapeutics and app-based cognitive behavioral therapy are emerging.
• The field is moving towards treating the combined psychological and biological causes.

We also completed a content validity study designed to identify and document the genital arousal symptoms that are the most important and relevant to women with FSAD. The findings of this study helped facilitate alignment with the FDA on acceptable efficacy endpoints for the Phase 2b RESPOND study and a future Phase 3 program.

Do They Work?

At the conclusion of the development program, if successful, Daré intends to leverage the existing safety and efficacy data for sildenafil to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% for the treatment of women in the U.S. DOI: 10.1016/j.sxmr.2016.03.002 Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016. The drug's controversial approval yesterday comes on the heels of two previous unsuccessful attempts, lingering questions about safety, and uncertainty about whether or not it really works. After three applications, ownership by two drug companies, and one successful lobbying campaign, the female sexual-dysfunction drug flibanserin was approved yesterday by the Food and Drug Administration.

Let's do it.

Flibanserin, which will be sold under the brand name Addyi, has been billed as a remedy for women liquid viagra with Hypoactive Sexual Desire Disorder, defined as “persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity” in either gender. It’s also been rejected twice, for concerns that lingered even after an FDA advisory committee voted 18-6 in June to recommend approval. The drug has an effectiveness rate of somewhere between 8 and 13 percent, and can cause side effects like fainting, dizziness, and low blood pressure, many of which were found to be exacerbated by alcohol and hormonal contraception. When it comes to market in October, Addyi’s label will carry a warning that it can’t be taken with alcohol. (And in the alcohol-safety study submitted to the FDA, oddly, 23 of the 25 participants were men, meaning the effects of drinking while on the drug still aren’t fully understood for the women who will be taking it.) Even so, it’s been hailed by supporters as a step towards gender equality in a previously overlooked area.

CONVENIENT & DISCREET

“The FDA has approved 26 drugs marketed for the treatment of male sexual dysfunctions, compared to zero [now one] to address the most common form of female sexual dysfunction,” reads the website for Even the Score, a coalition of non-profits and health-care companies—including Sprout Pharmaceuticals, which makes flibanserin—that formed in 2013 to lobby for the drug’s approval. None of those 26 drugs, though, has the same purpose as flibanserin. Viagra and its ilk enhance physical arousal; despite its nickname as the “pink Viagra,” flibanserin was developed to enhance desire. Viagra is taken before sex and increases blood flow to the genitals; flibanserin is supposed to be taken daily and aims further north, changing the balance of neurotransmitters in the brain. The comparisons to Viagra, and the bumpy road to approval, have raised complicated questions about the nature of female desire, sexism in drug research, and what ought to qualify as a disorder. The Phase 2b study was an exploratory study to evaluate a number of primary endpoints and secondary endpoints as well as to identify a target patient population for Sildenafil Cream, 3.6%. The Phase 2b clinical study was designed as a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD). Study participants used Sildenafil Cream and placebo cream over 12 weeks in their home setting, following both a non-drug and placebo cream run-in period. All participants had a main diagnosis of FSAD and may have also had concomitant sexual dysfunction diagnoses or symptoms including decreased desire, orgasmic dysfunction, and genital pain. Exploratory Phase 2b clinical study designed to evaluate Sildenafil Cream vs.

Ready to see why DARE to PLAY could be the best you've ever had?

ADDYI can cause serious side effects, including: See “What is the most important information I should know about ADDYI?” This is not a complete list of side effects. ADDYI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women < 65 years of age who have not had problems with low sexual desire in the past, no matter the type of sexual activity, situation, or sexual partner, and it is troubling to them. Their low sexual desire is not due to a medical or mental health problem, problems in the relationship, medicine or other drug use. ADDYI is not for use in men or to improve sexual performance. Female sexual arousal disorder (FSAD) FSAD, as described in the Diagnostic and Statistical Manual 4th Edition (DSM-IV), is a condition characterized as a persistent or recurrent inability to attain or maintain sufficient genital arousal (an adequate lubrication-swelling response) during sexual activity, frequently resulting in distress or interpersonal difficulty.

11 natural aphrodisiacs for females

Of the various types of female sexual dysfunction disorders, FSAD is most analogous to erectile dysfunction (ED) in men. There are currently no FDA-approved therapies for FSAD. A meta-analysis of 95 studies from 2000-2014 indicated prevalence of Female Sexual Dysfunction in premenopausal women worldwide is 41%, and difficulty with arousal alone is 23%.1 Market research estimates: 33% of US women aged 21 to 60 (~ 20 million women), experience symptoms of low or no sexual arousal.2,310 million women in the US are considered distressed and actively seeking treatment.2 33% of US women aged 21 to 60 (~ 20 million women), experience symptoms of low or no sexual arousal.2,3 10 million women in the US are considered distressed and actively seeking treatment.2 To put the market opportunity for an FDA-approved FSAD treatment in context, a PDE5 inhibitor utilized in an ED medication for men – Viagra® — peaked at $2.05 billion in sales in 2012.4 Orally administered sildenafil, a phosphodiesterase-5 (PDE-5) inhibitor, received FDA approval in 1998 for the treatment of erectile dysfunction in men and is marketed under the brand name Viagra®. Given the underlying pathophysiologic similarities of ED and FSAD, using sildenafil to direct blood to the genitals before sexual activity could provide a potential improvement in genital arousal response and overall sexual experience for women as it does in men. Sildenafil Cream, 3.6% is an investigational proprietary topical formulation of sildenafil being developed as a first-in-category option for women for the treatment of FSAD.

Increased genital blood flow

Unlike the oral formulations of PDE-5 inhibitors, sildenafil viagra price Sildenafil Cream is applied locally to the vaginal tissue and is designed to facilitate vasodilation and increased blood flow directly to the genital tissue to improve the physical arousal response symptoms commonly associated with FSAD while avoiding systemic side effects observed with oral formulations of sildenafil. Phase 1 and Phase 2a Clinical Studies, Previously Completed In a Phase 1 clinical study in 20 healthy post-menopausal women, topical sildenafil cream was safe and well tolerated at clinically relevant doses, and study subjects reported favorable product characteristics: easy to use and readily absorbed. In a Phase 2a study in women with FSAD (15 pre-menopausal and 16 post-menopausal), Sildenafil Cream increased measurable blood flow to the genital tissue compared to placebo cream. Further, data from a thermography study in healthy women demonstrated significantly greater increases in genital temperature after administration of Sildenafil Cream compared to placebo cream, indicating a positive impact on genital blood flow during the 30-minute testing session, with statistical separation from placebo within the first 15 minutes after dosing. We also completed a content validity study designed to identify and document the genital arousal symptoms that are the most important and relevant to women with FSAD. placebo over 12 weeks of double-blinded dosing following both a cheap viagra with dapoxetine non-drug and placebo run-in period: Compared Sildenafil Cream vs. placebo used in patients’ home setting.

Off-Label Use	Potential Risks	Medical Advice
Sildenafil for Female Libido	Cardiovascular side effects, interactions with other meds	Always consult a doctor before use
Non-approved supplements	Unknown composition, higher risk of adverse reactions	Use only if prescribed by a healthcare professional
DIY formulations	Dangerous, no clinical testing	Highly discouraged

Co-primary endpoints: patient reported outcome (PRO) instruments measured improvement in localized genital sensations of arousal (Arousal-Sensation Domain of the Sexual Function Questionnaire) and reduction in FSAD related distress (Female Sexual Distress Scale).

• A GP is the first point of contact for discussing sexual health concerns in the UK.
• They may conduct blood tests to check hormone levels (e.g., testosterone, estrogen).
• A full medical and psychological history is essential for an accurate diagnosis.
• GPs can refer patients to a specialist clinic, like a urogynaecology or sexual health service.
• Specialists may work in NHS hospitals or private practices.
• The British Society for Sexual Medicine provides guidelines for healthcare professionals.
• A diagnosis often involves ruling out other medical and relationship issues first.

Secondary endpoint: measured change in the number of satisfactory sexual events Exploratory endpoints: Several efficacy endpoints measured and could be candidate endpoints in a Phase 3 study. Efficacy assessments were administered both on an electronic diary to be completed within 24 hours of a sexual event and via 28-day recall assessments. Sildenafil Cream-treated group showed meaningful improvement in the co‑primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire, although the endpoint did not achieve statistical significance.1 Post-hoc analyses showed that Sildenafil Cream met the Ph2b co-primary endpoint (SFQ28-arousal domain patient reported outcome (PRO)) and demonstrated clinically meaningful benefit in patients who have FSAD or FSAD with concomitant decreased desire. Secondary and exploratory endpoints saw these patients report meaningful improvement in arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction.

• Online pharmacies like Superdrug Online Doctor offer private consultations.
• Boots Online Doctor provides a similar service for discreet access to treatments.
• LloydsPharmacy Online Doctor allows for private prescriptions following an assessment.
• The NHS provides treatment primarily for underlying causes like depression or menopause.
• Private clinics, such as The London Hormone Clinic, specialize in women's health.
• Costs for private prescriptions vary significantly, often £50-£100 per month.
• Always ensure any online provider is registered with the General Pharmaceutical Council.

Read more about the Phase 2b clinical study here.

If you're tired of uncertain quality and unproven options, you're not alone.

Regulatory Strategy for Sildenafil Cream, 3.6%: Next Steps The Company is working to align with the FDA on the Phase 3 study design. At the conclusion of the development program, if successful, Daré intends to leverage the existing safety and efficacy data for sildenafil to utilize the FDA’s 505(b)(2) pathway to obtain marketing approval of Sildenafil Cream, 3.6% for the treatment of women in the U.S. DOI: 10.1016/j.sxmr.2016.03.002 Ad Hoc Market Research: FSAD Prevalence Report (Oct 2015) conducted for SST LLC. Based on US Census projections for 2016.

Tip	Explanation	Source Reference
Consult a healthcare professional before use	To ensure safety and appropriateness	NHS guidelines
Purchase from licensed sources	To avoid counterfeit products	Medicines and Healthcare products Regulatory Agency (MHRA)
Know the possible side effects	Be aware of adverse reactions	UK MHRA drug safety updates
Avoid mixing with alcohol	To prevent interactions	UK health advice

The drug's controversial approval yesterday comes on the heels of two previous unsuccessful attempts, lingering questions about safety, and uncertainty about whether or not it really works.

HERE IS WHAT SHE SAYS...

After three applications, ownership by two drug companies, and one successful lobbying campaign, the female sexual-dysfunction drug flibanserin was approved yesterday by the Food and Drug Administration. Flibanserin, which will be sold under the brand name Addyi, has been billed as a remedy for women liquid viagra with Hypoactive Sexual Desire Disorder, defined as “persistently or recurrently deficient (or absent) sexual fantasies and desire for sexual activity” in either gender. It’s also been rejected twice, for concerns that lingered even after an FDA advisory committee voted 18-6 in June to recommend approval. The drug has an effectiveness rate of somewhere between 8 and 13 percent, and can cause side effects like fainting, dizziness, and low blood pressure, many of which were found to be exacerbated by alcohol and hormonal contraception. When it comes to market in October, Addyi’s label will carry a warning that it can’t be taken with alcohol.

• Flibanserin works on neurotransmitters in the brain, increasing dopamine and noradrenaline.
• It simultaneously decreases serotonin activity, which is thought to inhibit sexual desire.
• Bremelanotide is a melanocortin receptor agonist that acts on pathways in the brain.
• Ospemifene is a Selective Estrogen Receptor Modulator (SERM) with estrogen-like effects.
• Testosterone is thought to play a key role in libido for both men and women.
• Topical estrogens work by replenishing thinning vaginal tissues.
• Understanding the mechanism helps in choosing the right treatment for the cause.

(And in the alcohol-safety study submitted to the FDA, oddly, 23 of the 25 participants were men, meaning the effects of drinking while on the drug still aren’t fully understood for the women who will be taking it.) Even so, it’s been hailed by supporters as a step towards gender equality in a previously overlooked area. “The FDA has approved 26 drugs marketed for the treatment of male sexual dysfunctions, compared to zero [now one] to address the most common form of female sexual dysfunction,” reads the website for Even the Score, a coalition of non-profits and health-care companies—including Sprout Pharmaceuticals, which makes flibanserin—that formed in 2013 to lobby for the drug’s approval. None of those 26 drugs, though, has the same purpose as flibanserin. Viagra and its ilk enhance physical arousal; despite its nickname as the “pink Viagra,” flibanserin was developed to enhance desire. Viagra is taken before sex and increases blood flow to the genitals; flibanserin is supposed to be taken daily and aims further north, changing the balance of neurotransmitters in the brain.

Desire Starts in the Brain...

The findings of this study helped facilitate alignment with the FDA on acceptable efficacy endpoints for the Phase 2b RESPOND study and a future Phase 3 program. The Phase 2b study was an exploratory study to evaluate a number of primary endpoints and secondary endpoints as well as to identify a target patient population for Sildenafil Cream, 3.6%. The Phase 2b clinical study was designed as a multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of Sildenafil Cream, 3.6% in premenopausal patients with female sexual arousal disorder (FSAD). Study participants used Sildenafil Cream and placebo cream over 12 weeks in their home setting, following both a non-drug and placebo cream run-in period. All participants had a main diagnosis of FSAD and may have also had concomitant sexual dysfunction diagnoses or symptoms including decreased desire, orgasmic dysfunction, and genital pain.

Comparison table

Exploratory Phase 2b clinical study designed to evaluate Sildenafil Cream vs. placebo over 12 weeks of double-blinded dosing following both a cheap viagra with dapoxetine non-drug and placebo run-in period: Compared Sildenafil Cream vs. placebo used in patients’ home setting. Co-primary endpoints: patient reported outcome (PRO) instruments measured improvement in localized genital sensations of arousal (Arousal-Sensation Domain of the Sexual Function Questionnaire) and reduction in FSAD related distress (Female Sexual Distress Scale). Secondary endpoint: measured change in the number of satisfactory sexual events Exploratory endpoints: Several efficacy endpoints measured and could be candidate endpoints in a Phase 3 study.

Effects on sexual dysfunction

Efficacy assessments were administered both on an electronic diary to be completed within 24 hours of a sexual event and via 28-day recall assessments. Sildenafil Cream-treated group showed meaningful improvement in the co‑primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire, although the endpoint did not achieve statistical significance.1 Post-hoc analyses showed that Sildenafil Cream met the Ph2b co-primary endpoint (SFQ28-arousal domain patient reported outcome (PRO)) and demonstrated clinically meaningful benefit in patients who have FSAD or FSAD with concomitant decreased desire. Secondary and exploratory endpoints saw these patients report meaningful improvement in arousal sensation, desire, orgasm, as well as stress, guilt, and embarrassment about the sexual dysfunction. Read more about the Phase 2b clinical study here. Regulatory Strategy for Sildenafil Cream, 3.6%: Next Steps The Company is working to align with the FDA on the Phase 3 study design. The comparisons to Viagra, and the bumpy road to approval, have raised complicated questions about the nature of female desire, sexism in drug research, and what ought to qualify as a disorder. The drug’s approval has also raised a simpler question: What changed, exactly, between those two rejections and last night? The most obvious answer is good public relations. Even the Score, which launched in 2013, has framed the issue as one of “women’s sexual health equity.” The group notes on its site that the World Health Organization considers “[pursuit of] a satisfying, safe and pleasurable sexual life” to be a human right, and has successfully solicited letters of support to the FDA from the editor of The Journal of Sexual Medicine, the president of the National Organization for Women, and members of Congress.